Dr. Christopher Maher presented his research findings on 5-hydroxymethylcytosine as a liquid biopsy biomarker in colorectal cancer at the Cancer Genomics Consortium Annual Meeting in Houston Texas

The Cancer Genomics Consortium (CGC) 2025 Annual Meeting brought together the global clinical genomics community August 3–6 in Houston, Texas, with both in-person and virtual participation. The program featured keynote speakers, scientific sessions, abstract presentations, workshops, and networking opportunities—highlighting the latest advances in genomics and their impact on precision medicine and patient care.

🔗 Find out more about the meeting at Cancer Genomics Consortium’s website: CGC 2025 Annual Meeting